Background: The purpose of this study was to study the clinicopathological features of ovarian serous carcinoma in an Egyptian cohort as well as to uncover the potential role of Sox10 through evaluating immunohistochemical expression. Article History Volume 6, Issue 5, 2024 Received: 22 May 2024 Accepted: 03 Jun 2024 doi: 10.48047/AFJBS.6.5.2024. 9689-9710 Methods: A retrospective study was carried out on sixty seven cases diagnosed as ovarian serous carcinoma at the Oncologic pathology Department – National Cancer Institute – Cairo University, during the period from 1 st January 2015 to 31 st December 2017. Automated staining for Sox10 was done on BenchMark ULTRA. Results: The age of patients ranged from 26 to 76 years. The majority of cases had bilateral ovarian cancer; 43 cases (64%). Most of the cases; 30 cases (45%) were of FIGO stage III. Most of patients received adjuvant chemotherapy (69%). SOX10 expression in this research was completely negative in all studied case. Forty two cases (62.7%) had poor outcome; in the form of recurrence (32 cases; 47.8%), metastasis (7 cases; 10.5%), death (23 cases; 34.3%) or two events combined (18; cases; 26.9%). Median follow-up period was 38 months. A significant correlation was found between survival estimates and optimum debulking/minimal residual disease (p value= 0.001), FIGO stage (p value= 0.03), response to platinum based chemotherapy (p value = 0.004) Conclusions: High grade and low grade serous carcinomas are heterogeneous diseases with the need of new effective therapeutic strategies. SOX10 is not expressed in ovarian serous carcinoma.